Artia Global Partners’s Protagonist Therapeutics PTGX Stock Holding History

Artia Global Partners’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.81M	Buy	22,951 +20	+0.1%	+$2.09K	0.52%	38
2026 Q1	$2.42M	Sell	22,931 -20	-0.1%	-$1.77K	0.48%	34
2025 Q4	$2M	Hold	22,951	–	–	0.28%	38
2025 Q3	$1.52M	Hold	22,951	–	–	0.24%	39
2025 Q2	$1.27M	Sell	22,951 -310,900	-93%	-$14.9M	0.31%	29
2025 Q1	$16.1M	Buy	333,851 +40,000	+14%	+$1.68M	4.09%	8
2024 Q4	$11.3M	Buy	293,851 +169,411	+136%	+$7.39M	4.05%	14
2024 Q3	$5.6M	Hold	124,440	–	–	1.53%	13
2024 Q2	$4.31M	Hold	124,440	–	–	0.83%	17
2024 Q1	$3.6M	Buy	124,440 +12,100	+11%	+$329K	0.72%	19
2023 Q4	$2.58M	Hold	112,340	–	–	0.75%	17
2023 Q3	$1.87M	Hold	112,340	–	–	0.78%	19
2023 Q2	$3.1M	Buy	+112,340	New	+$2.81M	1.07%	22

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Artia Global Partners's PTGX Position: Q2 2026 in Review

Artia Global Partners increased its Protagonist Therapeutics (PTGX) stake by 0.09% in Q2 2026, buying an estimated $2.09K and bringing the position to 22,951 shares worth $2.81M. The position accounts for 0.52% of the portfolio, ranked #38.

Artia Global Partners first reported a position in PTGX in Q2 2023 and has held it in 13 quarters since. The position peaked at $16.1M in Q1 2025. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Artia Global Partners held 22,951 shares of Protagonist Therapeutics worth $2.81M as of Q2 2026.
Artia Global Partners bought 20 Protagonist Therapeutics shares in Q2 2026, an estimated $2.09K.
Protagonist Therapeutics made up 0.52% of Artia Global Partners's portfolio in Q2 2026, its #38 holding.
Artia Global Partners first reported a position in Protagonist Therapeutics in Q2 2023 and has held it in 13 quarters since.
Artia Global Partners's Protagonist Therapeutics position peaked at $16.1M in Q1 2025.
344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Artia Global Partners's 13F filing for Q2 2026, filed 14 Aug 2026.